1. Home
  2. NKSH vs MDWD Comparison

NKSH vs MDWD Comparison

Compare NKSH & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NKSH

National Bankshares Inc.

N/A

Current Price

$33.87

Market Cap

185.2M

Sector

Finance

ML Signal

N/A

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$18.79

Market Cap

238.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKSH
MDWD
Founded
1891
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Major Banks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
185.2M
238.5M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
NKSH
MDWD
Price
$33.87
$18.79
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$37.50
AVG Volume (30 Days)
14.1K
84.8K
Earning Date
01-22-2026
11-20-2025
Dividend Yield
4.48%
N/A
EPS Growth
41.35
N/A
EPS
2.04
N/A
Revenue
$51,980,000.00
$20,932,000.00
Revenue This Year
$2.95
$15.89
Revenue Next Year
$9.97
$25.33
P/E Ratio
$16.49
N/A
Revenue Growth
19.63
6.15
52 Week Low
$23.75
$14.14
52 Week High
$35.00
$22.51

Technical Indicators

Market Signals
Indicator
NKSH
MDWD
Relative Strength Index (RSI) 65.56 54.69
Support Level $33.36 $18.55
Resistance Level $35.00 $18.96
Average True Range (ATR) 0.93 0.57
MACD 0.08 0.01
Stochastic Oscillator 77.43 55.79

Price Performance

Historical Comparison
NKSH
MDWD

About NKSH National Bankshares Inc.

National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: